BeOne Newsroom

• May 28, 2026

  BeOne Medicines Receives Positive Reimbursement Recommendations from CDA-AMC and INESSS for TEVIMBRA in First-Line Nasopharyngeal Carcinoma

• December 23, 2025

  Health Canada Approves TEVIMBRA® (tislelizumab for injection) in Combination with Gemcitabine and Cisplatin for the First-Line Treatment of Adult Patients with Recurrent or Metastatic Nasopharyngeal Carcinoma

• May 27, 2025

  BeOne Medicines Launches Following Redomiciliation to Switzerland, Marking a New Chapter in Global Oncology

• October 29, 2024

  BeiGene Canada Proud National Sponsor of the Leukemia & Lymphoma Society of Canada’s 2024 Light The Night

• May 8, 2024

  Biotech Leader, BeiGene, Inaugurates Office in Toronto, Canada

• February 7, 2024

  Health Canada Approves BRUKINSA® (zanubrutinib) for the Treatment of Relapsed or Refractory Follicular Lymphoma

• January 31, 2024

  Adults living with chronic lymphocytic leukemia (CLL) in Ontario and Quebec now have access through public reimbursement to BRUKINSA® (zanubrutinib)

• May 30, 2023

  Health Canada Approves BRUKINSA® (zanubrutinib) for the Treatment of Chronic Lymphocytic Leukemia (CLL), the Most Common Leukemia in Adult

• February 6, 2023

  Quebec becomes first province to cover BRUKINSA® (zanubrutinib) for the Treatment of Waldenström’s macroglobulinemia

• January 9, 2023

  BeiGene Canada Named a Great Place to Work®

• April 8, 2021

  BeiGene Launches BRUKINSA® (Zanubrutinib) in Canada for Patients with Waldenström’s Macroglobulinemia